Key result
Most endogenous plasma NT-BNP in patients with heart or renal failure is glycosylated, and the relative percentage of glycosylated NT-BNP significantly increases after haemodialysis (p<0.0001).
Why the study?
How does glycosylation affect the measurement and levels of plasma NT-BNP in patients with heart failure or chronic renal failure?
Observational (n=262)
How does glycosylation affect the measurement and levels of plasma NT-BNP in patients with heart failure or chronic renal failure?
p-value: p=<0.0001
Most endogenous plasma NT-BNP is glycosylated and therefore underestimated by current standard assays, with relative glycosylation levels further increased by haemodialysis.
No takes yet. Share an insight, caveat, or question.
Current NT-proBNP assays likely underestimate true levels in HF and CRF; leaves open need for glycosylation-adjusted thresholds in diagnostics and trials.
Nishikimi et al. (2011) conducted an observational in Heart failure and chronic renal failure (n=262). Haemodialysis vs. Before haemodialysis was evaluated on Percentage of glycosylated NT-BNP (p=<0.0001). Most endogenous plasma NT-BNP in patients with heart or renal failure is glycosylated, and the relative percentage of glycosylated NT-BNP significantly increases after haemodialysis (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: